

REVIEW

## Nutritional and Environmental Approaches to Preventing and Treating Autism and Attention Deficit Hyperactivity Disorder (ADHD): A Review

LUKE T. CURTIS, M.D., C.I.H., M.S.,<sup>1</sup> and KALPANA PATEL, M.D., F.A.A.P., F.A.A.E.M.<sup>2,3</sup>

### ABSTRACT

**Objectives:** The purpose of this study was to concisely review the available literature of nutritional and environmental factors on autistic spectrum and attention deficit hyperactivity disorder (ADHD).

**Design and methods:** Review of journal articles found on the PubMed database and from information from several conference proceedings.

**Results:** Many, but not all, studies link exposure to toxins such as mercury, lead, pesticides, and *in utero* smoking exposure to higher levels of autism and/or ADHD. Some studies have reported many nutritional deficiencies in autism/ADHD patients. Numerous studies have reported that supplemental nutrients such as omega-3 fatty acids, vitamins, zinc, magnesium, and phytochemicals may provide moderate benefits to autism/ADHD patients. Avoidance of food allergens, food chemicals, and chelation therapy may also provide some relief to autism/ADHD patients.

**Conclusions:** Autistic spectrum disorders and ADHD are complicated conditions in which nutritional and environmental factors play major roles. Larger studies are needed to determine optimum multifactorial treatment plans involving nutrition, environmental control, medication, and behavioral/education/speech/physical therapies.

### INTRODUCTION

Autism, a chronic disorder with onset before 3 years, presents with a wide range of stereotyped, repetitive behaviors, social difficulties, and language abnormalities.<sup>1–3</sup> The recent total prevalence of autism, Asperger's syndrome, and related developmental disorders is estimated at between 40 and 60 per 10,000 children.<sup>4</sup> Attention deficit hyperactivity disorder (ADHD) is an extremely common condition affecting 8% to 12% of children worldwide.<sup>5</sup> About 40% to 80% of autistic spectrum children also have ADHD as a comorbid disorder.<sup>6–9</sup>

Psychosocial factors certainly play a significant role in

autism and ADHD disorders. Many studies have indicated that behavioral therapy and medications are often at least partially helpful for children with autistic spectrum and/or ADHD.<sup>10–16</sup> However, much recent research has suggested that nutritional and environmental factors also play a major role in the development of autism and ADHD disorders.

This paper will attempt to provide a broad review of the available literature on nutritional and environmental aspects of the epidemiology, etiology, prevention, and treatment of autistic spectrum disorders and ADHD. A second paper by the same authors will describe a pilot study of multi modal treatment (nutrition, chelation, environmental control, and

<sup>1</sup>Occupational Physician and Industrial Hygienist, Wilmette, IL.

<sup>2</sup>Medical Director, Environmental Health Center, Buffalo, NY.

<sup>3</sup>Clinical Assistant Professor of Pediatrics, SUNY, Buffalo, NY.

psychosocial therapies) of 10 children with a combined diagnosis of autistic spectrum and ADHD.<sup>17</sup>

## MATERIALS AND METHODS

This review is based upon extensive review of the PubMed database, as well as information from proceedings from several conferences on autism and/or ADHD.

## RESULTS AND DISCUSSION

### *Toxic chemicals and autism*

Much attention has focused on possible links between exposure to mercury, lead, and other toxics and autism. Some studies have found that exposure to vaccines with the mercury-containing preservative thimerosal is associated with significantly higher rates of autism,<sup>18</sup> while other studies have found no association between thimerosal-containing vaccines and autism.<sup>19–21</sup> A British prospective study of 13,647 singleton births recorded whether or not children received thimerosal-containing vaccines by 93 or 124 days after birth.<sup>21</sup> This study also analyzed whether or not children developed any of 23 behavioral, fine motor, speech, and other problems relating to autistic spectrum.<sup>21</sup> Of 46 analyses, receiving thimerosal-containing vaccines was associated with a significantly increased incidence of 1 adverse effect (reduced prosocial behavior by children who received vaccine before 93 days), no statistically significant effect in 41 comparisons, and associated with a significantly reduced adverse effect for 4 comparisons (conduct problems and fine motor skills in children receiving thimerosal before 93 days and tics and development of special needs in those children who received thimerosal vaccines before 124 days).<sup>21</sup> A review by the U.S. Food and Drug Administration (FDA) in 2001 concluded that there was no evidence of risk of thimerosal in vaccines apart from local hypersensitivity reactions.<sup>22</sup> A study 1047 children 7–10 years of age found that exposure to thimerosal-containing vaccines prenatally or up to age 7 months was rarely associated with any significant positive or negative outcomes in 42 neuropsychologic tests.<sup>23</sup> Higher prenatal thimerosal exposure was associated with 1 significantly positive and 1 significantly negative neuropsychologic outcome in 42 tests as compared to unexposed children.<sup>23</sup> Higher exposure to thimerosal-containing vaccines from birth to 7 months was associated with 2 significantly positive and no significantly negative neuropsychologic outcomes.<sup>23</sup> The incidence of autistic spectrum disorders was not measured in this study.<sup>23</sup>

Hair mercury levels averaged 15 times higher in 40 Kuwaiti autistic children as compared to 40 healthy controls (4.50 versus 0.30  $\mu\text{g/g}$  hair,  $p < 0.001$ ).<sup>24</sup> On the other hand, a Singapore study reported little difference in mean hair mer-

cury in 82 autistic children versus 55 controls (2.26 versus 2.07  $\mu\text{g/g}$  hair,  $p = 0.79$ ).<sup>25</sup> An Arizona study found that levels of mercury in baby teeth were 2.1 times as high in a group of 15 autistic children as compared to 11 healthy controls ( $p < 0.05$ ).<sup>26</sup> Levels of zinc and lead were similar in both autistic and control children.<sup>26</sup> Average antibiotic use in first year of life was 3.6 in the autistic children and 1.5 in the controls ( $p < 0.001$ ).<sup>26</sup>

A study of 1184 Texas elementary/ high school districts found that higher levels of environmentally released mercury were associated with significantly higher levels of autism rates and rates of special education services.<sup>27</sup> A California study of 284 autistic children and 657 controls found that living in areas with higher outdoor air concentrations of mercury, cadmium, vinyl chloride, and trichloroethylene were all associated with significantly higher rates of autistic spectrum disorder.<sup>28</sup> A California case-control study reported that children born to mothers who lived within 500 m of agricultural organochlorine spraying had an odds ratio risk of autistic spectrum disorders of 6.1 (95% confidence interval (CI) of 2.4–15.3) as compared to children whose mothers did not live near areas of agricultural organochlorine spraying.<sup>29</sup>

Several studies have examined urinary levels of metals in autistic children following oral chelation therapy with meso-2,3-dimercaptosuccinic acid (DMSA). A Maryland study determined urinary metal levels following DMSA challenge in a group of 7 autistic children with no known mercury exposures except from thimerosal in vaccines.<sup>30</sup> Urinary mercury levels exceeded the reference level of 3  $\mu\text{g}$  Hg/g creatinine in all 7 patients, and urinary lead levels exceeded the reference level of 15  $\mu\text{g}$  Pb/g creatinine in 2 of 7 of the children.<sup>30</sup> On the other hand, another study of 15 autistic children given a DMSA challenge reported that urinary mercury levels were elevated in only 1 of the children, and urinary lead levels were elevated in 0 of the 15 autistic children.<sup>31</sup>

### *Toxic chemicals and ADHD*

Hair lead levels have been found to be significantly higher in children with autism and/or ADHD in some,<sup>24,32</sup> but not all studies,<sup>33–34</sup> Many studies have indicated that childhood lead exposure can reduce IQ and attention and cause hyperactivity at levels below the current 10  $\mu\text{g/dL}$  blood lead standard.<sup>35–37</sup> A U.S. study of 97 children with ADHD and 53 control children reported that higher blood lead levels were associated with significantly higher levels of ADHD symptoms.<sup>38</sup> In this study, mean blood lead levels were modest (1.04  $\mu\text{g/dL}$ ) and maximum blood lead levels were 3.4  $\mu\text{g/dL}$ .<sup>38</sup> A Chinese case-control study reported that blood mercury levels exceeding 29 nmol/L were associated with a significantly greater risk of ADHD.<sup>39</sup> A study of 4704 U.S. children reported that significantly higher levels of ADHD were found in children exposed to tobacco smoking *in utero*

and in children with higher blood lead concentrations.<sup>40</sup> A Quebec study reported that higher manganese levels in hair and drinking water were associated with significantly higher levels of hyperactive behaviors in schoolchildren.<sup>41</sup> A study of 780 children with high lead levels (20–44  $\mu\text{g}/\text{dL}$ ) reported that treatment with 1–3 26-day courses of succimer chelation therapy significantly reduced blood lead levels but did not result in any significant changes in tests of neuropsychologic function, cognition, or behavior.<sup>42</sup>

#### *Impaired detoxification enzymes in autism*

Autistic children often have lower levels of detoxification enzymes and antioxidants and may therefore be more susceptible to environmental toxics. Autistic children have significantly lower mean levels of detoxification/antioxidant enzymes such as paroxonase,<sup>43,44</sup> sulphation enzymes,<sup>45</sup> glutathione peroxidase,<sup>46</sup> and superoxide dismutase.<sup>46</sup> Significantly lower levels of methionine, *s*-adenosyl methionine, cysteine, and reduced glutathione were found in a group of 80 autistic children as compared to 73 controls ( $p < 0.0001$  in all cases).<sup>47</sup> Another study of 8 autistic children found that reduced blood glutathione levels were significantly below normal in 6 children, blood cysteine levels were below normal in 6 children, and blood sulfate concentrations below normal in 4 patients.<sup>30</sup> A French study reported that urinary levels of coproporphyrin and precoproporphyrin (markers of lead exposure) were significantly higher in 106 autistic children as compared to 12 controls.<sup>48</sup> On the other hand, a Utah study reported that plasma levels of metallothionein (a metal-detoxifying protein) were similar in 60 autistic children and 50 controls.<sup>49</sup>

#### *Nutritional factors in autism and ADHD*

Nutritional deficiencies may also play a major role in autism. Significantly lower levels of nutrients in blood, hair, and other tissues have been seen in autistic children including low levels of magnesium,<sup>50</sup> zinc,<sup>51</sup> selenium,<sup>51</sup> vitamins A, B-complex, D, and E,<sup>51</sup> omega-3 fatty acids,<sup>52,53</sup> and carnitine.<sup>54</sup> A study of 861 autistic children and 123 control children found that feeding infant formulas lacking added docosahexaenoic acid (DHA) and arachidonic acids was associated with a 4.41 increased odds (95% CI 1.24–15.7) of developing autistic spectrum disorder as compared to breast-fed infants.<sup>55</sup>

Some studies have reported that nutritional interventions can significantly help many patients with autism and/or ADHD. A double-blind, placebo-controlled study of 20 autistic children reported that use of a broad-based multivitamin and mineral supplement was significantly helpful in reducing sleep and gastrointestinal symptoms, and non-significantly helpful in improving behavior and receptive language.<sup>56</sup> A double-blind, placebo-controlled study found that supplementation of L-carnosine in autistic children produced significant improvement in the Gilliam Autism

Scale.<sup>57</sup> Other studies have reported some improvement in autistic children supplemented with vitamin B<sub>6</sub>,<sup>58</sup> folate,<sup>58</sup> omega-3 fats,<sup>59</sup> and vitamin C.<sup>60</sup> Oral supplementation with magnesium and vitamin B<sub>6</sub> significantly improved social interactions, communications, and intellectual function in the children with autistic-spectrum.<sup>61</sup> Case histories have reported that various nutrients such as cod liver oil,<sup>62</sup> carnitine,<sup>63</sup> and coenzyme Q<sub>10</sub><sup>63</sup> appear to help individual autistic patients.

Some studies have reported that ADHD patients have significantly lower levels of omega-3 fatty acids in their blood phospholipids and red blood cell membranes.<sup>64,65</sup> Use of supplements containing omega-3 fatty acids have been helpful to ADHD patients in some but not all studies. An Australian study found that ADHD children given capsules containing 2400 mg fish oil and 600 mg evening primrose oil daily for 15 weeks had significant improvements in many areas of the Conners Parental rating scales relating to hyperactivity and inattention as compared to ADHD children given placebo.<sup>66</sup> However, this study also found no significant changes in any of the Conners Teacher rating scales for either the treatment or placebo group of ADHD children.<sup>66</sup> An Indian study found that daily supplementation with 50 mg of vitamin C and flax oil containing 400 mg of  $\alpha$ -linolenic acid daily significantly improved symptoms of inattention, hyperactivity, learning problems, and social problems in 30 children with ADHD.<sup>67</sup> Levels of omega-3 fatty acids in the red blood cells of these children also increased significantly following supplement with flax oil.<sup>67</sup> Several studies have found that evening primrose supplementation significantly improves symptoms of inattention (but not hyperactivity) in children with ADHD.<sup>68,69</sup> An Indiana study compared 4 months' treatment with a supplement containing fish oil and evening primrose oil versus olive oil placebo on 50 children with ADHD.<sup>64</sup> Children receiving the fish/evening primrose oil supplement had significant improvements in behavior symptoms on the parental-rated Disruptive Behavior Disorder Rating Scale and in teacher-rated inattention symptoms as compared to children given olive oil placebo.<sup>64</sup> However, no significant improvements in the Conners ADHD scales or in tests of memory and audiovisual processing were seen in the fish/evening primrose oil-treated patients versus placebo.<sup>64</sup> This study also reported that supplementation with fish/evening primrose oil resulted in a significant increase in blood phospholipid and red blood cell levels of omega-3 fatty acids such as DHA and eicosapentaenoic acid.<sup>64</sup>

On the other hand, a Texas study of ADHD children reported that daily supplementation of 345 mg daily of the omega-3 fatty acid DHA did not significantly improve any symptoms of inattention and impulsivity as compared to placebo.<sup>70</sup> Another study involving 18 boys with ADHD reported that use of 4000 mg evening primrose oil capsules produced little improvement in ADHD symptoms as compared to placebo.<sup>71</sup> The only factor in this study to signifi-

cantly improve with administration of evening primrose oil was a significant improvement in teacher rated hyperactivity symptoms.<sup>71</sup>

Double-blind, placebo-controlled studies have reported that supplements of carnitine<sup>72</sup> and zinc<sup>73,74</sup> have been helpful in treating ADHD symptoms. Some studies have found that magnesium and vitamin B<sub>6</sub> supplements significantly reduce excitability and improve concentration in ADHD children.<sup>75,76</sup> However, an Ohio study reported that the use of magnesium and vitamin B<sub>6</sub> supplements was ineffective in treating 10 patients with autistic disorder.<sup>77</sup> Another study found that a dried supplement containing broccoli, cabbage, carrots and other phytonutrients was helpful in reducing ADHD symptoms.<sup>78</sup> Significant improvement in attention and visual/auditory response was noted in 10 ADHD children given a broad range of supplements containing vitamins, minerals, phytonutrients, amino acids, omega-3 fats, and probiotic bacteria.<sup>79</sup>

Blood levels of iron are often low in ADHD patients. A French study reported that serum ferritin levels averaged only 23 ng/mL in 53 children with ADHD but averaged 44 ng/mL in 27 control children ( $p < 0.001$ ).<sup>80</sup> Some studies have reported that supplementation of the diet with metals such as iron, calcium, and zinc can decrease lead absorption in humans and experimental animals.<sup>81</sup> However, a study of 602 lead-exposed Mexican children found that daily supplementation with 30 mg of ferrous fumarate, zinc oxide, or both was not associated with any changes in parent- and teacher-rated symptoms of inattention, hyperactivity, or cognition.<sup>82</sup>

### *Allergies and food intolerances in autism and ADHD*

Allergies and intolerances to food and food additives may also play a role in autism and ADHD. Elimination of potentially allergenic foods such as casein and gluten have been tried on autistic children with mixed results. A Norwegian study found that 10 children with autism on a casein- and gluten-free diet for 1 year improved on autistic traits, cognition, and motor skills to a significantly greater extent than 10 children given a standard diet.<sup>83</sup> On the other hand, a Florida double-blind crossover trial of 13 children with autism found that behavior did not differ significantly between the 6 weeks on a gluten- and casein-free diet versus 6 weeks on the standard diet.<sup>84</sup> Other studies have reported that children with autism have a significantly higher rate of increased intestinal permeability ("leaky gut syndrome") compared to controls.<sup>85</sup> Some researchers have suggested that oral probiotic bacteria supplements may be helpful in treating autism.<sup>63</sup>

The effect of refined sugar and food additives on ADHD patients is controversial, with some, but not all, studies showing that sugar and food additives can trigger worsened ADHD symptoms.<sup>86</sup> A review of 16 studies with ADHD

children found that sugar challenges were associated with worsened symptoms of inattention and hyperactivity in 4 studies, little change in 11 studies, and improvement in ADHD symptoms in 1 study.<sup>87</sup>

Diets free of food coloring, food preservatives, and natural salicylates have been widely used to treat children with ADHD since they were introduced in the 1970s by Dr. Benjamin Feingold.<sup>87</sup> A meta-analysis of 15 double-blind, placebo-controlled studies in patients with ADHD reported that artificial colors such as tartrazine significantly increased ADHD symptoms (overall effect size of 0.283, 95% CI 0.079–0.488).<sup>88</sup> Of the 15 individual studies, 5 showed that food colors were associated with significantly increased ADHD, 8 showed that food colors were associated with non-significant increases in ADHD symptoms, and 2 showed that food colors were associated with nonsignificant decreases in ADHD symptoms.<sup>88</sup> Besides food colors, other dietary components that may possibly worsen ADHD symptoms include food preservatives such as benzoate, nitrates, and monosodium glutamate as well as food that naturally contains salicylates (such as almonds, oranges, raspberries, apples, cherries, grapes, peaches, strawberries, cucumbers, plums, and tomatoes).<sup>89</sup>

## CONCLUSIONS

Both autism and ADHD appear to involve a broad range of genetic, prenatal, social, developmental, nutritional, and environmental factors, and it is unlikely that only 1 single cause will be found for either disorder.<sup>63,90–93</sup> Multiple treatment modalities are probably needed to treat patients with autism and/or ADHD and may include nutritional, environmental, pharmacologic, and psychosocial interventions. A small pilot study of multiple treatments for 10 patients with autistic spectrum and ADHD has been conducted by us.<sup>17</sup> Larger, well-controlled studies in the future will be needed to determine optimal multimodal treatment plans for patients with autism and/or ADHD.

## REFERENCES

1. Bailey A, Phillips W, Rutter M. Autism: Toward an integration of clinical, genetic, neuropsychological and neurobiological perspectives. *J Child Psychol Psychiatry* 1996;37:89–126.
2. Rapin I. The autistic spectrum disorders. *N Engl J Med* 2002; 347:302–303.
3. Volkmar FR, Pauls D. Autism. *Lancet* 2003;362:1131–1141.
4. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: An update. *J Autism Dev Disord* 2003;33:365–382.
5. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. *Lancet* 2005;366:237–248.
6. Leyfer OY, Folstein SE, Bacalman S, et al. Comorbid psychiatric disorders in children with autism: Interview develop-

- ment and rates of disorders. *J Autism Dev Disord* 2006;36:849–861.
7. Matson JL, Nebel-Schwalm MS. Comorbid psychopathology with autism spectrum disorder: An overview. *Res Dev Disabil* 2007;28:341–352.
  8. Lee DO, Ousley OY. Attention deficit hyperactivity samples in a clinic sample of children and adolescents with pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 2006;16:737–746.
  9. Yoshida Y, Uchiyama T. The clinical necessity for assessing attention deficit/hyperactivity disorder (AD/HD) symptoms in children with high-functioning pervasive developmental disorder (PDD). *Eur Child Adolesc Psychiatry* 2004;13:307–314.
  10. Filapek PA, Steinberg-Epstein R, Book TM. Intervention for autistic spectrum disorders. *NeuroRx* 2006;3:207–216.
  11. Howlin P. The effectiveness of interventions for children with autism. *J Neural Trans (Suppl)* 2005;69:101–119.
  12. Volkmar FR, Lord C, Bailey A, et al. Autism and pervasive developmental disorders. *J Child Psychol Psychiatry* 2004;45:135–170.
  13. Daley D. Attention deficit hyperactivity disorder: A review of the essential facts. *Child Care Health Dev* 2006;32:193–204.
  14. Steer CR. Managing attention deficit disorder: Unmet needs and future directions. *Arch Dis Child* 2005;90:S19–S25.
  15. Campbell-Daley K. Update on attention-deficit hyperactivity disorder. *Curr Opin Pediatr* 2004;16:217–226.
  16. Daly BP, Creed T, Xanthopoulos M, Brown RT. Psychosocial treatments for children with attention deficit/hyperactivity disorder. *Neuropsychol Res* 2007;17:73–89.
  17. Patel K, Curtis L. A comprehensive treatment approach to treating autism and attention deficit hyperactivity disorder. *J Altern Complement Med* 2007;13:1091–1097.
  18. Geier DA, Geier MR. An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DPTH vaccine in the United States. *J Toxicol Environ Health* 2006;69:1481–1495.
  19. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data. *Pediatrics* 2004;114:793–804.
  20. Uchiyama Y, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: Negative results presented from Japan. *J Autism Dev Disord* 2007;37:210–217.
  21. Heron J, Golding J; ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: A prospective cohort study in the United Kingdom does not support a causal relationship. *Pediatrics* 2004;114:577–583.
  22. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. *Pediatrics* 2001;107:1147–1154.
  23. Thomsson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. *N Engl J Med* 2007;357:1281–1292.
  24. Fido A, Al-Saad S. Toxic trace elements in the hair of children with autism. *Autism* 2005;9:290–298.
  25. Ip P, Wong V, Ho M, et al. Mercury exposure in children with autistic spectrum disorder: A case-control study. *J Child Neurol* 2004;19:431–434.
  26. Adams JB, Romdalvik J, Sadagopa Ramanujam VW, Legator MS. Mercury, lead and zinc in baby teeth of children with autism versus controls. *J Toxicol Environ Health Part A* 2007;70:1046–1051.
  27. Palmer RF, Blanchard S, Stein Z, et al. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. *Health Place* 2006;12:203–209.
  28. Windham GC, Zhang L, Gunier R, et al. Autism spectrum disorders in relation to distribution of hazardous air pollutants in the San Francisco Bay area. *Environ Health Perspect* 2006;114:1438–1444.
  29. Roberts EM, English PE, Grether JK, et al. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. *Environ Health Perspect* 2007 (in press). Online document at: <http://dx.doi.org/> document doi:10.1289/ehp.10168. Accessed July 30, 2007.
  30. Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. *J Toxicol Environ Health* 2007;70:837–851.
  31. Soden SE, Lowry JA, Garrison CB, Wasserman GS. 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls: A pilot study. *Clin Toxicol (Phila)* 2007;45:476–481.
  32. Tuthill RW. Hair lead levels related to children's classroom attention-deficit behavior. *Arch Environ Health* 1996;51:214–220.
  33. Shearer TR, Larson K, Neuschwander J, Gedney B. Minerals in the hair of autistic children. *J Autism Dev Disord* 1982;12:25–34.
  34. Kern JK, Grannemann BD, Trivedo MH, Adams JB. Sulfhydryl-reactive metals in autism. *J Toxicol Environ Health A* 2007;15:715–721.
  35. Stein J, Schettler T, Wallinga D, Valenti M. In harm's way: Toxic threats to child development. *J Dev Behav Pediatrics* 2002;23:S13–S22.
  36. Thomson GO, Raab GM, Hepburn WS, et al. Blood-lead levels and children's behaviour: Results from the Edinburgh Lead Study. *J Child Psychol Psychiatry* 1989;30:515–528.
  37. Munoz H, Romieu I, Palazuelos E, et al. Blood lead level levels and neurobehavioral development among children living in Mexico City. *Arch Environ Health* 1993;48:132–139.
  38. Nigg JT, Knottnerus M, Martel M, et al. Low blood lead levels associated with clinically diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control. *Biol Psychiatry* 2008 (in press).
  39. Cheuk DK, Wong V. Attention-deficit hyperactivity disorder and blood mercury levels: A case-control study in Chinese children. *Neuropediatrics* 2006;37:234–240.
  40. Braun J, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. *Environ Health Perspect* 2006;114:1904–1909.
  41. Bochard M, Lafirest F, Vandelaec L, et al. Hair manganese and hyperactive behaviors: Pilot study of children exposed through tap water. *Environ Health Perspect* 2007;115:122–127.
  42. Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. *N Engl J Med* 2001;344:1421–1426.
  43. Pasca SP, Nemes B, Vlase L, et al. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. *Life Sci* 2006;78:2244–2248.

44. D'Amelio M, Ricci I, Sacco R, et al. Paraoxonase gene variants are associated with autism in North America, but not in Italy: Possible regional specificity in gene-environment interactions. *Mol Psychiatry* 2005;10:1006-1016.
45. Alberti A, Pirrone P, Elia M, et al. Sulphation deficit in "low functioning" autistic children: A pilot study. *Biol Psychiatry* 1999;46:420-424.
46. Yorbik O, Sayai A, Akay C, et al. Investigation of antioxidant enzymes in children with autistic disorder. *Prostaglandins Leukotr Essent Fatty Acids* 2002;67:341-343.
47. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. *Am J Med Genet* 2006;141:947-956.
48. Nataf R, Skorupka C, Amet L, et al. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. *Toxicol Appl Pharmacol* 2006;214:99-108.
49. Singh VK, Hanson J. Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thiomerosal. *Pediatr Allergy Immunol* 2006;17:291-296.
50. Strambi M, Longini M, Hayek J, et al. Magnesium profile in autism. *Biol Trace Elem Res* 2006;109:97-104.
51. Adams JB, Audhya T, Vogelaar T. Nutritional abnormalities in autism and effects of nutritional supplementation: 2003 conference proceedings of the National Autism Society of America, Pittsburgh, PA, July 16-20, 2003.
52. Chen JR, Hsu SF, Hsu CD, et al. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. *J Nutr Biochem* 2004;15:467-472.
53. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acids levels in autistic children. *Prostaglandins Leukotr Essent Fatty Acids* 2001;65:1-7.
54. Filapek PA, Juarenk J, Nguyen MT, et al. Relative carnitine deficiency in autism. *J Autism Dev Disord* 2004;34:615-623.
55. Schultz SS, Klonoff-Cohen HS, Wingard DL, et al. Breast-feeding, infant formula supplementation, and autistic disorder: The results of a patient survey. *Int Breastfeed J* 2006;15:16.
56. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. *J Altern Complement Med* 2004;10:1033-1039.
57. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorder. *J Child Neurol* 2002;17:833-837.
58. Rimland B. Controversies in the treatment of autistic children: Vitamin and drug therapy. *J Child Neurol* 1988;3:S68-S72.
59. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled study. *Biol Psychiatry* 2007;61:551-553.
60. Dolske MC, Spollen J, McKay S. A preliminary trial of ascorbic acid as a supplemental therapy for autism. *Prog Neuropsychopharmacol Biol Psychiatry* 1993;17:765-774.
61. Mousain-Bosc M, Roche M, Polge A, et al. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder—autism. *Magnes Res* 2006;19:53-62.
62. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? *Med Hypotheses* 2000;54:979-983.
63. Kidd PM. Autism, an extreme challenge to integrative medicine: Part 2. Medical management. *Altern Med Rev* 2002;7:472-499.
64. Stevens L, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity and other disruptive behaviors. *Lipids* 2003;38:1007-1021.
65. Antalis CJ, Stevens LJ, Campbell M, et al. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. *Prostaglandins Leukotr Essent Fatty Acids* 2006;75:299-308.
66. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. *J Dev Behav Pediatrics* 2007;28:82-91.
67. Joshi K, Lad S, Kale M, et al. Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). *Prostaglandin Leukotri Essen Fatty Acids* 2006;74:17-21.
68. Aman MG, Mitchell EA, Turbott SH. The effects of fatty acid supplementation by Efamol on hyperactive children. *J Abnorm Child Psychol* 1987;15:75-90.
69. Richardson AJ, Puri BK. A randomized, double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD related symptoms in children with specific learning difficulties. *Prog Neurosychopharmacol Biol Psychiatry* 2002;26:233-239.
70. Voight RG, Llorente AM, Jensen CL, et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention deficit/hyperactivity disorder. *J Pediatr* 2001;139:189-196.
71. Arnold LE, Kleykamp D, Votolato NA, et al. Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in ADHD. *J Child Adolesc Psychopharmacol* 1994;4:171-180.
72. Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention deficit disorder. *Prostaglandins Leukotr Essent Fatty Acids* 2002;67:33-38.
73. Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2004;28:181-190.
74. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double-blind and randomised trial. *BMC Psychiatry* 2004;4:9-14.
75. Mousain-Bosc M, Roche M, Polge A, et al. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6: II. Attention deficit hyperactivity disorders. *Magnes Res* 2006;19:46-52.
76. Mousain-Bosc M, Roche M, Rapin J, Balik JP. Magnesium-vitamin B6 intake reduces central nervous system hyperexcitability in children. *J Am Coll Nutr* 2004;23:545S-548S.
77. Findling RL, Maxwell K, Scotese-Wojtila A, et al. High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in double-blind, placebo controlled study. *J Autism Dev Disord* 1997;27:467-478.
78. Dykman KD, Dykman RA. Effect of nutrition supplements on attentional-deficit hyperactivity disorder. *Integrat Physiol Behav Sci* 1998;33:49-60.

79. Harding KL, Judah RD, Grant C. Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD. *Altern Med Rev* 2003;8:319–330.
80. Konofal E, Lecendreux M, Arnulf I, Mouren MC. Iron deficiency in children with attention-deficit/hyperactivity disorder. *Arch Pediatr Adolesc Med* 2004;158:1113–1115.
81. Peraza MA, Ayala-Fierro F, Barber DS, et al. Effects of micronutrients on metal toxicity. *Environ Health Perspect* 1998;106(suppl 1):203–216.
82. Kordas K, Stolfus RJ, Lopez P, et al. Iron and zinc supplementation does not improve parent or teacher ratings of behavior in first grade Mexican children exposed to lead. *J Pediatr* 2005;147:632–639.
83. Knivsberg AM, Reichelt KL, Høien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. *Nutr Neurosci* 2002;5:251–261.
84. Elder JH, Shankar M, Shuster J, et al. The gluten-free, casein-free diet in autism: Results of a preliminary double blind clinical trial. *J Autism Dev Disord* 2006;36:413–420.
85. White JF. Intestinal pathophysiology in autism. *Exper Biol Med* 2003;228:639–649.
86. Schnoll R, Burshteyn D, Cea-Aravena J. Nutrition in the treatment of attention-deficit disorder: A neglected but important aspect. *Appl Psychophysiol Biofeedback* 2003;28:63–75.
87. Rojas NJ, Chan E. Old and new controversies in the alternative treatment of attention deficit hyperactivity disorder. *Mental Retard Develop Disabil Res Rev* 2005;11:116–130.
88. Schab DW, Trihn NT. Do artificial food colors promote hyperactivity in children with hyperactivity syndromes? A meta-analysis of double-blind placebo-controlled trials. *Dev Behav Pediatr* 2004;25:423–434.
89. Beseler L. Effects on behavior and cognition: Diet and artificial colors, flavors, and preservatives. *Int Pediatr* 1999;14:41–43.
90. Kidd PM. Attention deficit/hyperactivity disorder (ADHD) in children: Rationale for its integrative management. *Altern Med Rev* 2000;5:402–428.
91. Daniels JL. Autism and the environment [editorial]. *Environ Health Perspect* 2006;114:A396.
92. Hertz-Picciotto I, Croen LA, Hansen R, et al. The CHARGE Study: An epidemiologic investigation of genetic and environmental factors contributing to autism. *Environ Health Perspect* 2006;114:1119–1125.
93. Hapke F, Ronald A, Plomin R. Time to give up on a single explanation for autism. *Nature Neurosci* 2006;9:1218–1220.

Address reprint requests to:  
*Luke Curtis, M.D.*  
1328 Greenwood Avenue  
Wilmette, IL 60091

*E-mail:* LukeTCurtis@aol.com

Copyright of *Journal of Alternative & Complementary Medicine* is the property of Mary Ann Liebert, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.